ArticleBone & joint research2026
FGF9 attenuates osteoarthritis progression through the NRF2/GPX3 antioxidant axis.
Article in Bone & joint research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Aims: Osteoarthritis (OA), a prevalent age-related joint disease affecting over 250 million people globally, currently lacks effective disease-modifying treatments. Fibroblast growth factor 9 (FGF9) has shown cartilage-protective effects in post-traumatic OA models, but its role in chondrocyte degeneration and OA pathogenesis remains unclear. This study investigates FGF9's function in human and murine chondrocytes and its therapeutic potential for OA. Methods: Gene expression profiling was performed on primary chondrocytes from OA patients and normal controls. Senescence and reactive oxygen species (ROS) levels were assessed by β-galactosidase staining and flow cytometry. FGF9 function was evaluated through short hairpin RNA (shRNA)-mediated knockdown and treatment with FGF9-conditioned media (CM). The impact of FGF9-enriched exosomes on chondrocyte senescence was also examined in vitro. In vivo effects were tested using adenovirus-delivered FGF9 in a destabilization of the medial meniscus (DMM)-induced OA mouse model. Results: FGF9 expression was significantly downregulated in OA chondrocytes (n = 195) compared to normal (n = 71). FGF9 knockdown elevated ROS levels and senescence via suppression of the NRF2/GPX3 antioxidant axis, while FGF9 promoted chondrogenesis in mesenchymal stem cells. Intra-articular FGF9 gene therapy reduced OA progression in DMM mice. Additionally, FGF9-enriched exosomes reduced senescence in primary chondrocytes in vitro. Conclusion: FGF9 alleviates OA progression by activating the NRF2/GPX3 pathway, reducing ROS and chondrocyte senescence. These findings support the therapeutic potential of FGF9 and FGF9-enriched exosomes in OA treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.